Introduction

Background
Migraine is an episodic central nervous system disorder characterized by vascular headache associated with vasodilatation of extra-cranial vessels but may be due to disturbed neuronal activity in the hypothalamus 1 . Migraine headache ranges from moderate to very severe in intensity and lasts from 4 to 72 hours 2 , often accompanied by photophobia, phonophobia and vomiting 3 .
According to World Health Organization (WHO) migraine is the global burden of health related issue that study was conducted in 2000 and reported in the World Health Report 4 . Successful management of migraine requires intensive patient's educations and through physician knowledge about available treatment options and strategies 5 .
Migraine is a common condition, annually affecting 12% of the United States population, including 18% of women, 6% of men and 4% of children. Migraine is generally more common in people who are in lower socioeconomic groups 6 .
In Bangladesh there is no data regarding the prevalence of migraine. In a study conducted in BSMMU headache clinic total 3440 of headache patients were studied and 16.05% of them had a diagnosis of migraine 7 .
Different elements need to be considered in migraine management. They include avoidance of triggering factors, lifestyle modifications, non-pharmacological therapies and lastly medications. Pharmacological treatment is traditionally divided into acute treatment, and preventive treatment. Many migraine patients can be treated using only acute treatment that is used only during headache attacks to abort an ongoing attack. Patients with severe and/or frequent migraines require long-term preventive therapy 8 .
Prophylaxis is recommended to reduce the frequency and/ or intensity of migraine when patients experience more than three to five attacks per month. A variety of drugs are in use for migraine prevention. Adrenergic receptor blockers (e.g. propranolol), tricyclic antidepressants (e.g. amitriptyline), anticonvulsants (e.g. topiramate and valproate), and serotonergic drugs (e.g. methysergide) are most commonly administered for this purpose, as summarized in US Headache Consortium Guidelines. Topiramate showed statistically significant efficacy in migraine prevention. Among several treatment-emergent adverse events dose dependent weight loss is common. For these reason, slow titration of target dose of topiramate is advisable 9 .
Propranolol has been prescribed for migraine prophylaxis since 1966.The usual propranolol doses for migraine prevention from 80 to 160 mg a day 10 . In a clinical trial comparing the efficacy of propranolol with sodium valproate in migraine prophylaxis in BSMMU showed that 53.17% decline in headache frequency, 64.81% decline in headache duration &15.16% decline in headache severity, whereas 48.98% decline in headache frequency, 62.84% decline in headache duration & 18.15% decline in headache severity 11 .
Propranolol has already been established itself as a comparator drug. Physicians are on the hunt for an alternative drug which might be superior to propranolol in efficacy or having at least same efficacy but can be used in situations where propranolol is contraindicated. For the last few years, high dose (100-200 mg/day) topiramate was used in migraine prophylaxis, but with such high doses, usually significant side effect could have occurred. 12 In this context, the present study was designed to observe the effect of low dose topiramate (50 mg/day) in migraine prophylaxis comparing it with propranolol (80 mg/day) in respect of efficacy, adverse effect & to see superiority or equality among Bangladeshi population. . Considering 10% drop out in every follow up, sample size was 120 by using N=16/(E/S) 2 formula. A total 120 patients were selected according to selection criteria.
Materials and Methods
This
Inclusion criteria
1. Patient of migraine (with typical aura or without aura) according to ICHD-3 criteria.
2. Age at entry: 18-50 years.
3. Patients not on any prophylactic medication.
4. Patients willing to take part in the study. 
Results
Total 120 patients in the age range of 18 to 50 years diagnosed as migraine (with aura or without aura) according to ICHD-3 criteria, were recruited as study population. Total 96 patients were completed the study due to drop out of 13 patients in group-I & 11 patients in group-II in different steps of follow up. Table-IV shows that mean (SD) value of frequency of migraine attack was found 9.28 (2.39) in group-I and that of 9.29 (2.46) in group-II. During 1 st follow up, nonsignificant differences in frequency of migraine attack were observed but there was more decreasing value in patients of group-II than that of group-I .During 2 nd follow up, there was statistically significant difference (p=0.024) was observed in frequency of migraine attack between group-I and group-II. Table-V shows that during 1 st follow up, statistically nonsignificant differences was observed but between groups there was more decreasing value in patients of group-II than that of group-I. During 2 nd follow up, statistical significant (p=0.047) difference was observed in duration of migraine attack between group-I and group-II. Table-VI shows that at baseline level, there was no statistical significant difference between group-I and group-II. During 1st follow up, patients were distributed in mild, moderate and severe groups but no statistical significant difference was found. In 2 nd follow up, patients had better condition and distributed in mild and moderate groups. There was statistical significant (p < 0.05) difference between group-I and group-II. 
Discussion
Various drugs have been used for migraine prophylaxis. In the present study, efficacy and safety of topiramate and propranolol were compared. Among the many different beta-blockers, propranolol is one of the most commonly prescribed for migraine prophylaxis 12 . Recently, antiepileptic drugs including topiramate (TPM) are more commonly used in adults and adolescents for migraine prophylaxis.
There are substantial number of study demonstrating the efficacy of topiramate and propranolol in the treatment of migraine 13 . It is one of the clinical trials of migraine to compare topiramate and propranolol in Bangladesh context. We compared our study findings with result of some other published articles elsewhere in the world.
Analysis of age distribution showed that, the mean age was found 29.72±9.58 years in group-I and mean age were 30.96±10.11 years in group-II but no significant difference in age distribution among both groups. A good number of the study patients were 18-25 years age group in both groups (42.6% vs. 42.9% 13 found that the topiramate group showed more reduction in migraine frequency than propranolol group. These results are not similar to this study probably due to racial variation. 17 .
In present study, efficacy and adverse effect of topiramate and propranolol were compared and results showed that both drugs were effective in reduction of frequency, duration and severity of headache but propranolol was more effective than topiramate. Furthermore, in topiramate group, patients complained of more adverse effects than propranolol group (23.4% vs. 14.3%). So, comparative studies of propranolol with topiramate showed that topiramate was more effective especially in Iran (Ashtari et al. 2008 ) 13 but present study showed that, propranolol is more effective than topiramate in migraine prophylaxis probably due to poor metabolism of propranolol in our regional context (Correia, 2009) 18 .
Conclusion
Considering statistical analyses, topiramate and propranolol both are individually safe and effective for migraine prophylaxis in reduction of frequency, severity and duration of migraine. But propranolol is more effective than topiramate in respect of reducing frequency, severity and duration of migraine.
